Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2023-01-08 Investor Presentation
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Imugene Presentation to the JP Morgan Healthcare Conference 38 pages 4.7MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about Imugene Limited, a biotech company, focusing on its cancer immunotherapy pipeline, clinical trials, technology platforms, management team, and scientific data. It includes extensive information on clinical trial phases, therapeutic approaches, and scientific mechanisms. The document is structured as a presentation with slides, images, and detailed scientific and clinical data. There is no indication that this is an official annual or interim financial report, audit report, earnings release, or regulatory filing. It is not a transcript of a call, nor a voting result or capital update. The content is clearly aimed at investors and stakeholders to provide a comprehensive overview of the company's strategy, pipeline, and clinical progress. This matches the definition of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2023-01-08 English
Letter to Shareholders 8 pages 180.2KB
AGM Information Classification · 95% confidence The document is a detailed letter to shareholders from Imugene Limited dated 6 January 2023. It provides a comprehensive update on the company's clinical progress, business development, industry presentations, collaborations, research publications, manufacturing, investor relations, financial position, human resources, and share price performance. The content is narrative and informative, aimed at updating shareholders on the company's status and outlook rather than announcing voting results, changes in management, or regulatory filings. It is not a formal annual or interim financial report, nor is it a transcript of a call or a presentation. The letter is a shareholder communication providing a broad update on company affairs, which fits the category of AGM Information (AGM-R) as it resembles materials shared during an annual general meeting or shareholder update. The document length (15,000 characters) and detailed content support this classification rather than a brief announcement or regulatory filing.
2023-01-05 English
Ceasing to be a substantial holder 2 pages 82.2KB
Regulatory Filings
2022-12-21 English
Notification regarding unquoted securities - IMU 6 pages 28.6KB
Capital/Financing Update Classification · 95% confidence The document is a notification regarding the issue of unquoted equity securities by Imugene Limited. It details the number and type of securities issued, dates, and mentions employee incentive schemes. The content is focused on the issuance of securities, including options, and references compliance with ASX listing rules. There is no financial performance data, management discussion, or earnings information. The document is an announcement of a capital issuance event rather than a full financial report or management commentary. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2022-12-21 English
Notification regarding unquoted securities - IMU 10 pages 36.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Notification of Issue, Conversion or Payment up of Unquoted Equity Securities' and details the issuance of unquoted options under an employee incentive scheme. It includes specifics such as the number of securities issued, exercise prices, expiry dates, and mentions key management personnel receiving securities. The document is an announcement of securities issuance rather than a financial report or detailed analysis. It does not contain financial statements or management discussion but focuses on the issuance of new securities and compliance with listing rules. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes.
2022-12-21 English
Change of Director's Interest Notice x6 16 pages 366.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including shares and options acquired or disposed, nature of interest (direct or indirect), and dates of changes. The document is a formal notification to the ASX about directors' personal share transactions. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document is not an annual report, earnings release, or any other financial report type, nor is it a regulatory announcement or proxy material. Therefore, the correct classification is DIRS (Director's Dealing). The document length and detail support a high confidence score.
2022-12-19 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.